Abnormalities of the nucleus basalis in Down's syndrome
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
One of the most striking manifestations of Down's syndrome is profound mental retardation. Furthermore, after 35 years of age, many patients with Down's syndrome develop clinical and pathological features of Alzheimer's disease. Since brains of patients with Alzheimer's disease show significant loss of neurons in the nucleus basalis of Meynert (nbM), we sought to establish normal standards of nbM neurons in persons with Down's syndrome and to determine whether reductions in the number of neurons occur with increasing age. The number and size of neurons in the nbM were measured in selected sagittal sections from 5 patients with Down's syndrome and 5 age‐matched controls. The patients (age range, 16 to 56 years) had 29% fewer nbM neurons than controls, and the oldest patient had the lowest cell count of all subjects. The size of nbM neurons did not differ significantly between the two groups. Our results show that the nbM contains fewer neurons in young persons with Down's syndrome than in normal controls and suggest that the number of these nerve cells may be further reduced in older persons with Down's syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Self-citationMesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Self-citation
Cited by
The influences of age on olfaction: a review
Doty, R. L., & Kamath, V. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.00020 · Cited by 634
Mesulam, M., & Geula, C. (1988) · Journal of Comparative Neurology · doi:10.1002/cne.902750205 · Cited by 518
Suh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 467
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome
Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448
The history of the cholinergic hypothesis
Contestabile, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.044 · Cited by 374
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B., & Gentleman, S. M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1392-5 · Cited by 368
The pathological association between down syndrome and Alzheimer disease
Mann, D. M. A. (1988) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(88)90041-3 · Cited by 347
Cooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336
Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Down syndrome: the brain in trisomic mode
Dierssen, M. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3314 · Cited by 274
The neurobiologie consequences of down syndrome
Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90074-2 · Cited by 248
Carlesimo, G. A., Marotta, L., & Vicari, S. (1997) · Neuropsychologia · doi:10.1016/s0028-3932(96)00055-3 · Cited by 211
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome.
Belichenko, P. V., Kleschevnikov, A. M., Masliah, E., Wu, C., Takimoto‐Kimura, R., Salehi, A., & Mobley, W. C. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21895 · Cited by 141
“Similarity in alterations of excitatory-inhibitory relationship in subjects with DS and Ts65Dn mice Most of the neuropathological literature for DS subjects has focused on cholinergic neurotransmitter systems (Casanova et al., 1985; Mann et al., 1985; see also review in Salehi et al., 2007).”
BackgroundCommunication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome
Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134
Dendritic and histochemical development and ageing in patients with Down's syndrome
TAKASHIMA, S., IIDA, K., MITO, T., & ARIMA, M. (1994) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.1994.tb00394.x · Cited by 126
Ayberk Kurt, M., Ilker Kafa, M., Dierssen, M., & Ceri Davies, D. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.075 · Cited by 126
The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome
Gibb, W. R., Mountjoy, C. Q., Mann, D. M., & Lees, A. J. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.2.193 · Cited by 122
García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100
Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Choi, J. H. K., Berger, J. D., Mazzella, M. J., Morales‐Corraliza, J., Cataldo, A. M., Nixon, R. A., Ginsberg, S. D., Levy, E., & Mathews, P. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06277.x · Cited by 83
Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
“SYN protein losses in the DS brain with AD may be linked to reports of neuronal loss [46-51] observed with age and with the presence of AD in these individuals.”
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Hart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
A unifying hypothesis of alzheimer’s disease: III—Risk factors
Heininger, K. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(200001)15:1<1::aid-hup153>3.0.co;2-1
Metadata
- Authors
- Casanova, M. F., Walker, L. C., Whitehouse, P. J., & Price, D. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1985-09
- Volume
- 18
- Issue
- 3
- Pages
- 310-313
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1985792428
- Cited by
- 201
- References
- 3
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.